Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBW 2992 plus cetuximab dose-finding study in EGFR-TKI resistant NSCLC
NL-OMON36313Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of afatinib and cetuximab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum tolerated dose and Recommended phase II dose. Started Sep 2010; status: active, not recruiting.
02
Drugs
afatinibcetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON36313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36313.